Skip to main content

Advanced Search

Projected result for your current search:: 0

Search Operators:

You can use operators in your search query to narrow down your results even more. Click on the search operator to see an explanation of how it works.
Finds documents with exactly this word group, in exactly this word order and spelling (e.g. "employer branding").
Finds documents with both search terms (e.g. sales AND bonus).
Finds documents with one or the other search term (e.g. porsche OR volkswagen).
Finds documents with all search terms. Blank space is understood as AND (e.g. man robot production).
Finds documents with no appearance of the word behind NOT (e.g. ford NOT "harrison ford").
Finds documents where the search term is mentioned at least "n" times."n" may be any number (e.g. COUNT(gear)>8).
Finds documents with both search terms in any word order, permitting "n" words as a maximum distance between them. Best choose between 15 and 30 (e.g. NEAR(recruit, professionals, 20)).
Finds documents with the search term in word versions or composites. The asterisk * marks whether you wish them BEFORE, BEHIND, or BEFORE and BEHIND the search term (e.g. lightweight*, *lightweight, *lightweight*).
Finds documents with the search term in different spellings. "?" allows only one character (e.g. organi?ation).
Special characters are understood as AND (e.g. Miller Bros. & Sons).
 Log in
Top
Drugs

Brensocatib: First Approval

Published in:
Author
Susan J. Keam
Published in
Drugs | Issue 2/2026

Abstract

Brensocatib (BRINSUPRI™), an oral, small molecule, reversible inhibitor of dipeptidyl peptidase 1 (DPP1), is being developed by Insmed Incorporated under license from AstraZeneca for the treatment of neutrophil-mediated diseases, including non-cystic fibrosis bronchiectasis (NCFB), chronic rhinosinusitis without nasal polyps (CRSsNP) and hidradenitis suppurativa (HS). Brensocatib received its first approval on 12 August 2025 in the USA for the treatment of NCFB in adult and paediatric patients 12 years of age and older. Brensocatib received a positive opinion in the EU on 17 Oct 2025 and is also under regulatory review in the UK for this indication. This article summarizes the milestones in the development of brensocatib leading to this first approval for the treatment of NCFB.
Title
Brensocatib: First Approval
Author
Susan J. Keam
Publication date
05-12-2025
Publisher
Springer International Publishing
Published in
Drugs / Issue 2/2026
Print ISSN: 0012-6667
Electronic ISSN: 1179-1950
DOI
https://doi.org/10.1007/s40265-025-02255-0
This content is only visible if you are logged in and have the appropriate permissions.
This content is only visible if you are logged in and have the appropriate permissions.

Other articles of this Issue 2/2026

Developments in Pharmacotherapy for Obstructive Sleep Apnoea: Unlocking the Potential for Targeted Treatment

Effect of Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) Inhibitors on Lipoprotein(a) Levels: An Umbrella Review of Meta-analyses of Randomized Controlled Trials

Paltusotine: First Approval

Correction: Ifupinostat: First Approval

Biased Kappa-opioid Agonist Strategies in Pain Management: Approaches to Clinical Benefits with Reduced Adverse Effects

Taletrectinib: First Approval

  • NSCLC
  • AdisInsight Report

Keynote webinar | Spotlight on dry eye disease

  • Live
  • Webinar | 28-05-2026 | 13:00 (CEST)

DED is highly prevalent yet challenging to diagnose and treat. Join leading experts to explore the latest developments and gain practical guidance on effective management in busy clinical settings. Brought to you by Springer Medicine and Eye.

Watch it live: 28 May 2026, 13:00–14:00 (CEST)

Prof. Harminder Dua
Prof. Sajjad Ahmad
Prof. Anat Galor
Join the webinar
Webinar
Image Credits
Conceptual illustration of dry eye disease/© Science Photo Library / Getty Images